Advertisement

Pharmacy World & Science

, Volume 29, Issue 5, pp 551–556 | Cite as

The use of Atypical antipsychotics in French psychiatric hospitals

  • Marie Christine BretEmail author
  • Pierre Bret
  • Antoine Pariente
  • Annie Fourier-Réglat
Research Article

Abstract

Objective

To study the prescribing practices of atypical antipsychotic drugs in French psychiatric hospitals.

Method

A 1-day cross-sectional observational survey was performed in seven psychiatric hospitals to study prescribing practices of the four atypical antipsychotics (AAP) marketed in France. These hospitals are members of the PIC network, a pharmacists’ working group based in southwestern France.

Main outcome measures

Type and dosages of prescribed atypical antipsychotics, indication and concomitant prescriptions.

Results

The study included 1475 adult inpatients’ prescriptions with an antipsychotic drug; 647 prescriptions included an AAP with risperidone and olanzapine accounting for about 70% cases. AAP prescriptions concerned psychotic patients in 65% of cases. Patients receiving an AAP in this indication were more likely to be male, were younger, and received higher daily doses than patients treated for other troubles. They were also more likely to receive associated neuroleptic and anticholinergic antiparkinsonian agents. There were 59 prescriptions (9.1%) for bipolar disorders. Clozapine wasn’t used in this indication. In 76.3% of cases, mood stabilizers were associated to the AAP prescribed in this indication.

Conclusion

This observational survey underlines the significant place taken by AAP for the treatment of psychiatric diseases in hospital prescribing practices. They show usage patterns of these drugs: dose, indications and concomitant medications, in line or not with current recommendations and reference guidelines. In bipolar disorders, AAPs seem more likely to be associated to an ongoing therapy using mood stabilizer than to replace it.

Keywords

Atypical antipsychotics France Guidelines Hospital pharmacy Prescribing Psychiatry 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

The authors would like to acknowledge all the participants who helped in data collection, and in particular, Dr Pierre Bret who performed the statistical analyses.

References

  1. 1.
    American Psychiatric Association (APA). Practice guideline for the treatment of patients with schizophrenia. Am J Psych 1997;154(Suppl 4)Google Scholar
  2. 2.
    Andem (National Agency for Development of Medical Evaluation) Recommendations and medical references: neuroleptic prescriptions. Concours Medical 1997;119:1441–5, 1609–14, 1767–73Google Scholar
  3. 3.
    Augry F, Esvan M. Prescription of atypical antipsychotics in a psychiatric hospital. Nervure 2001;IV: 7–13Google Scholar
  4. 4.
    Bret P, Bonnet F, Bret MC, Jaffre A. Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux): prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone. Encephale 2002;XXVIII:329–42Google Scholar
  5. 5.
    Brunot A, Lachaux B, Sontag H, Casadebaig F, Philippe A, Rouillon F et al. Pharmaco-epidemiological study on antipsychotic drug prescription in French psychiatry: patient characteristics, antipsychotic treatment and care management for schizophrenia. Encephale 2002;XXVIII: 129–38Google Scholar
  6. 6.
    Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998;59(suppl 12)Google Scholar
  7. 7.
    College of Quebec Clinicians. Schizophrenia treatment [Guidelines : Treating Schizoprenia] (June 1999). (on http://www.cmq.org/uploadedfiles/lignestraitementsschizophrenieang99.pdf)
  8. 8.
    Consensus Conference (THE). Strategies for long-term therapy of patients with schizophrenia. French federation of psychiatry, national agency for the development of medical evaluation and national union of friends and families of psychiatric patients (eds), Paris, 13 et 14 January 1994, 32 ppGoogle Scholar
  9. 9.
    Fabre Almaric E. Psychotropic drug prescriptions and corrector agent prescriptions in a French psychiatric hospital. Pharmacie Hospitaliere Française 1998;124:69–77Google Scholar
  10. 10.
    Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lepine JP, Begaud B. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 2000; 49:80–6PubMedCrossRefGoogle Scholar
  11. 11.
    Gury C, Berchot F, Fabre C, Surugue J, Welcomme N. Analysis of neuroleptics prescriptions in five specialized hospitals: comparison between hospital prescriptions and discharge prescriptions. L’information psychiatrique 2002;8:954–63Google Scholar
  12. 12.
    ICD 10/CIM 10. The ICD-10 Classification of Mental and Behavioural Disorders Clinical descriptions and diagnostic guidelines. 10th revision. Masson, 1994Google Scholar
  13. 13.
    Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lemperiere T. Consensus on the practical use of Amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology 2001;44:41–6PubMedCrossRefGoogle Scholar
  14. 14.
    Lehman AF, Steiwachs DM and the Co-investigators of the␣Port Project. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT). Treatment Recommendations. Schizophr Bull 1998;24(1):1–10PubMedGoogle Scholar
  15. 15.
    Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophren Res 1998;35:51–68CrossRefGoogle Scholar
  16. 16.
    McEvoy JP, Scheifler PL, Frances A. The Expert Consensus Guideline series: treatment of schizophrenia. J Clin Psychiatr 1999;60(suppl 11)Google Scholar
  17. 17.
    Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP. The Texas Medication Algorithm Project (TMAP): Schizophrenia algorithms. J Clin Psychiatr 1999; 60:649–657CrossRefGoogle Scholar
  18. 18.
    Rouillon F, Lachaux B, Fender P, Moreau Defarges T, Richard A, Chicoye A. Pharmaco-repidemiological study of risperidone prescription. La Lettre du Pharmacologue 2000;7:170–5Google Scholar
  19. 19.
    Taylor D, Mc Connell D, Mc Connell H, Abel K, Kervin R. The bethlem and maudsley NHS trust: prescribing guidelines., 5th ed., London: Martin Dunitz; 1999Google Scholar
  20. 20.
    Working Group for the Canadian Psychiatric Association and the Canadian alliance for Research on Schizophrenia. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998;43(suppl. 2)Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Marie Christine Bret
    • 1
    Email author
  • Pierre Bret
    • 1
  • Antoine Pariente
    • 2
  • Annie Fourier-Réglat
    • 2
  1. 1.Staff Pharmacist, Department of PharmacyCentre Hospitalier Charles PerrensBordeaux cedexFrance
  2. 2.Pharmacology department, EA 3676, IFR 99Universite Victor SegalenBordeauxFrance

Personalised recommendations